ADC Therapeutics SA (ADCT)

NYSE: ADCT · Real-Time Price · USD
2.770
+0.120 (4.53%)
At close: May 29, 2025, 4:00 PM
2.760
-0.010 (-0.37%)
After-hours: May 29, 2025, 6:34 PM EDT
4.53%
Market Cap 274.72M
Revenue (ttm) 75.82M
Net Income (ttm) -149.84M
Shares Out 99.18M
EPS (ttm) -1.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 710,783
Open 2.660
Previous Close 2.650
Day's Range 2.471 - 2.795
52-Week Range 1.050 - 4.130
Beta 1.55
Analysts Strong Buy
Price Target 7.75 (+179.78%)
Earnings Date May 14, 2025

About ADCT

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 15, 2020
Employees 265
Stock Exchange NYSE
Ticker Symbol ADCT
Full Company Profile

Financial Performance

In 2024, ADC Therapeutics's revenue was $70.84 million, an increase of 1.84% compared to the previous year's $69.56 million. Losses were -$157.85 million, -34.25% less than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ADCT stock is "Strong Buy." The 12-month stock price forecast is $7.75, which is an increase of 179.78% from the latest price.

Price Target
$7.75
(179.78% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ADC Therapeutics to Present at Upcoming Investor Conferences

LAUSANNE, Switzerland , May 15, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced par...

14 days ago - PRNewsWire

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Corporate Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Mohame...

15 days ago - Seeking Alpha

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab ...

15 days ago - PRNewsWire

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

ZYNLONTA ®  plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL Safety and tolerability data were consistent with the known...

15 days ago - PRNewsWire

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

LAUSANNE, Switzerland , May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...

21 days ago - PRNewsWire

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer Poster presentations highlight antitumor activit...

4 weeks ago - PRNewsWire

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th...

2 months ago - PRNewsWire

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Ne...

2 months ago - PRNewsWire

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

ADC Therapeutics SA (NYSE:ADCT) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Pepe C...

2 months ago - Seeking Alpha

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Complete...

2 months ago - PRNewsWire

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations LAUSANN...

2 months ago - PRNewsWire

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million ...

2 months ago - Seeking Alpha

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

LAUSANNE, Switzerland , March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced t...

2 months ago - PRNewsWire

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

LAUSANNE, Switzerland , Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th...

4 months ago - PRNewsWire

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

LAUSANNE, Switzerland , Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th...

5 months ago - PRNewsWire

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, u...

6 months ago - Seeking Alpha

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release...

6 months ago - PRNewsWire

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95...

6 months ago - PRNewsWire

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Company to host corporate update webcast to share results on December 11, 2024 LAUSANNE, Switzerland , Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host ...

6 months ago - PRNewsWire

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham - Investor Relations Ameet Mallik - Chief Executive Officer Pepe Carmona ...

7 months ago - Seeking Alpha

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside – Here's Why

7 months ago - Benzinga

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of ...

7 months ago - PRNewsWire

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation ...

7 months ago - PRNewsWire

ADC Therapeutics to Present at November Investor Conferences

LAUSANNE, Switzerland , Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced par...

7 months ago - PRNewsWire

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

LAUSANNE, Switzerland , Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th...

7 months ago - PRNewsWire